Recommendations from the EGAPP Working Group: Routine testing for Factor v Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members

Genetics in Medicine

Volumn 13, Issue 1, 2011, Pages 67-76

[No Author Info available]

Author keywords

Factor V Leiden; prothrombin; venous thromboembolism

Indexed keywords

ALANINE; ANTICOAGULANT AGENT; ARGININE; BLOOD CLOTTING FACTOR 5 LEIDEN; GLUTAMINE; GLYCINE; PLACEBO; PROTHROMBIN; WARFARIN; XIMELAGATRAN;

ADOLESCENT; ADULT; AMINO ACID SUBSTITUTION; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL ASSESSMENT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG DOSE COMPARISON; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTERNAL VALIDITY; FAMILY HISTORY; GENE MUTATION; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INTERNAL VALIDITY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COUNSELING; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; RISK BENEFIT ANALYSIS; RISK FACTOR; SECONDARY PREVENTION; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOPHILIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

FACTOR V; FAMILY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 78751633462     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e3181fbe46f     Document Type: Article

References (55)

1. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-1828.
2. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. Evidence report/technology assessment no. 180. AHRQ publication no. 09-E011, prepared by Johns Hopkins University Evidence Based Practice Center under contract no. HHSA 290-2007-10061-1. Rockville, MD: Agency for Healthcare Research and Quality, 2009.
3. Teutsch SM, Bradley LA, Palomaki GE, et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group. Genet Med 2009;11:3-14.
4. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ 3rd. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593.
5. White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:I4-I8.
6. Hansson PO, Sörbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160:769-774.
7. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768.
8. Schafer AI. Venous thrombosis as a chronic disease. N Engl J Med 1999; 340:955-956.
9. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ, American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(suppl 6):454S-545S. (Pubitemid 351892971)
10. Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 2004;350:2558-2563.
11. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001;344:1222-1231.
12. Stein PD, Hull RD, Kayali F, Ghali WA, Alshab AK, Olson RE. Venous thromboembolism according to age: the impact of an aging population. Arch Intern Med 2004;164:2260-2265.
13. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-1389.
14. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. The Columbus Investigators. N Engl J Med 1997;337: 657-662.
15. Simonneau G, Sors H, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-669.
16. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
17. Chang MH, Lindegren ML, Butler MA, et al. Prevalence in the United States of selected candidate gene variants: Third National Health and Nutrition Examination Survey, 1991-1994. Am J Epidemiol 2009;169:54-66.
18. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of Factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305-1307.
19. Spector EB, Grody WW, Matteson CJ, et al. Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med 2005;7:444-453.
20. Kujovich J (Updated March 9, 2010). Factor V Leiden thrombophilia. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2010. Available at: http://www.genetests.org. Accessed July 13, 2010.
21. Rosendaal FR, Reitsma PH. Genetics of venous thrombosis. J Thromb Haemost 2009;7(suppl 1):301-304.
22. Makelburg AB, Veeger NJ, Middeldorp S, et al. Different risk of deep vein thrombosis and pulmonary embolism in carriers with Factor V Leiden compared with non-carriers, but not in other thrombophilic defects. Results from a large retrospective family cohort study. Haematologica 2010;95:1030-1033.
23. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of Factor V or prothrombin or both. Br J Haematol 2000;111:1223-1229.
24. Emmerich J, Rosendaal FR, Cattaneo M, et al. Combined effect of Factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001;86:809-816.
25. Manten B, Westendorp RG, Koster T, Reitsma PH, Rosendaal FR. Risk factor profiles in patients with different clinical manifestations of venous thromboembolism: a focus on the Factor V Leiden mutation. Thromb Haemost 1996;76:510-513.
26. Emadi A, Crim MT, Brotman DJ, et al. Analytic validity of genetic tests to identify Factor V Leiden and prothrombin G20210A. Am J Hematol 2010; 85:264-270.
27. Segal JB, Brotman DJ, Necochea AJ, et al. Predictive value of Factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. JAMA 2009;301:2472-2485.
28. ACCE review: venous thromboembolism. ACCE model system for collecting, analyzing and disseminating information on genetic tests, 2004. Available at: http://www.cdc.gov/genomics/gtesting/ACCE/FBR/index.htm. Accessed July 8, 2010.
29. Hertzberg M, Neville S, Favaloro E, McDonald D. External quality assurance of DNA testing for thrombophilia mutations. Am J Clin Pathol 2005; 123:189-193.
30. Secretary's Advisory Committee on Genetics, Health, and Society. U.S. system of oversight of genetic testing: a response to the charge of the secretary of health and human services, 2008. Available at: http://oba.od.nih. gov/oba/SACGHS/reports/SACGHS-oversight-report.pdf. Accessed October 13, 2010.
31. Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with Factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998;128:15-20.
32. Lensen R, Rosendaal F, Vandenbroucke J, Bertina R. Factor V Leiden: the venous thrombotic risk in thrombophilic families. Br J Haematol 2000;110: 939-945.
33. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999;81: 198-202.
34. Couturaud F, Kearon C, Leroyer C, et al. Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have Factor V Leiden. Thromb Haemost 2006;96:744-749.
35. Martinelli I, Battaglioli T, De Stefano V, et al. The risk of first venous thromboembolism during pregnancy and puerperium in double heterozy-gotes for Factor V Leiden and prothrombin G20210A. J Thromb Haemost 2008;6:494-498.
36. Martinelli I, Legnani C, Bucciarelli P, Grandone E, De Stefano V, Mannucci PM. Risk of pregnancy-related venous thrombosis in carriers of severe inherited thrombophilia. Thromb Haemost 2001;86:800-803.
37. Tormene D, De Stefano V, Grandone E, et al. The G20210A prothrombin variant and the risk of venous thromboembolism or fetal loss in pregnant women: a family study. J Thromb Haemost 2007;5:2193-2196.
38. Tormene D, Simioni P, Prandoni P, et al. Factor V Leiden mutation and the risk of venous thromboembolism in pregnant women. Haematologica 2001; 86:1305-1309.
39. Hindorff LA, Burke W, Laberge AM, et al. Motivating factors for physician ordering of Factor V Leiden genetic tests. Arch Intern Med2009;169:68-74.
40. Laberge AM, Psaty BM, Hindorff LA, Burke W. Use of Factor V Leiden genetic testing in practice and impact on management. Genet Med 2009;11: 750-756.
41. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434.
42. Kearon C, Julian JA, Kovacs MJ, et al. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood 2008;112:4432-4436.
43. Wåhlander K, Eriksson H, Lundström T, et al. Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism. Br J Haematol 2006;133:68-77.
44. Schulman S, Wåhlander K, Lundström T, Clason SB, Eriksson H, THRIVE III Investigators. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349: 1713-1721.
45. Vossen CY, Walker ID, Svensson P, et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005;25:1992-1997.
46. Eckman MH, Singh SK, Erban JK, Kao G. Testing for Factor V Leiden in patients with pulmonary or venous thromboembolism: a cost-effectiveness analysis. Med Decis Making 2002;22:108-124.
47. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428.
48. van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993;153:1557-1562.
49. Hirsh J, Lee AY. How we diagnose and treat deep vein thrombosis. Blood 2002;99:3102-3110.
50. Grody WW, Griffin JH, Taylor AK, Korf BR, Heit JA, ACMG Factor V. Leiden Working Group. American College of Medical Genetics consensus statement on Factor V Leiden mutation testing. Genet Med 2001;3:139-148.
51. Van Cott EM, Laposata M, Prins MH. Laboratory evaluation of hyperco-agulability with venous or arterial thrombosis. Arch Pathol Lab Med 2002; 126:1281-1295.
52. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of Factor V leiden (R506Q) testing for the diagnosis and management of thromboem-bolic disorders. Arch Pathol Lab Med 2002;126:1304-1318.
53. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010;149:209-220.
54. Nicolaides AN, Breddin HK, Carpenter P, et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005;24:1-26.
55. Pernod G, Biron-Andreani C, Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009;34:156-203.